Sterility Concerns Prompt Cancer Med Recall

Concerns over sterility have prompted Avella of Deer Valley Inc. to recall 730 prefilled syringes containing bevacizumab 2.5 mg/0.1 mL (NDC 42852-001-27), according to the June 5, 2019, US Food and Drug Administration (FDA) Enforcement Report. 

The affected syringes are from 138-20191202@64 (Exp. 5/13/19) and were distributed throughout the United States. 

Avella of Deer Valley voluntarily initiated the recall May 3, 2019. On May 29, 2019, the FDA designated the recall Class II. The classification suggests use of the product could cause temporary or medically reversible adverse health consequences. Although the likelihood is remote, a possibility of serious harm also exists. 

Bevacizumab is a prescription medication used in the treatment of numerous cancers, including kidney, cervical, ovarian, colon, and rectal cancer. 

—Jolynn Tumolo